Abgenix About
Abgenix:
ABX-PTH as a potential treatment for secondary hyperparathyroidism (SHPT).
Key
Statistics for Abgenix
Abgenix develops and commercializes antibody-based
therapeutics. Their goal is to create and sustain long-term shareholder value
through a diversified strategy that minimizes risk while maximizing opportunity.
Abgenix focuses on delivering high-quality antibodies for a range of
disease targets. The company has generated hundreds of these antibodies, several
of which are currently in clinical trials. With a successful track record, Abgenix
has built a reputation for generating antibodies rapidly, efficiently and cost
effectively.
Products:
ABX-EGF
and ABX-MA1 -- two antibody product candidates that are being evaluated for potential
oncology indications.
About ABX-EGF (panitumumab)
Abgenix's most advanced
antibody product candidate is ABX-EGF (panitumumab), a fully human monoclonal
antibody generated using XenoMouse® technology. ABX-EGF targets the epidermal
growth factor receptor (EGFr), which is over-expressed in a variety of cancers
including lung, breast, bladder, pancreatic, colorectal, kidney and head and neck
cancer.
NIH
Clinical Trials:
Phase
II Drug:
ABX-EGF Colorectal
Cancer Metastases NIH
Link Phase
II Drug:
ABX-EGF Colorectal
Cancer Metastase NIH
Link Phase
I Drug:
panitumumab (ABX-EGF) Tumor
NIH
Link phase
I/PhaseII Drug:
AMG 706 Drug:
AMG 706 NIH
Link
More on Abgenix:
Analyst
Opinion
Analysts Estimates